2 papers in the library · publishing 2023
medRxiv Preprint Server July 3, 2023 Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al. preprint
Ketamine helps some patients with treatment resistant depression, but reliable methods for predicting which patients will respond are lacking.
medRxiv Preprint Server June 28, 2023 Mohammad Ali Shenasa, Houtan Totonchi Afshar, Eric A. Miller et al. preprint
Cannabis use may weaken the antidepressant effects of ketamine and repetitive transcranial magnetic stimulation (rTMS). The antidepressant effects of these treatments rely on long-term potentiation and synaptic plasticity, but cannabis activates CB1 receptors, which can impair synaptic plasticity. This suggests that cannabis use might reduce the effectiveness of ketamine and rTMS for depression treatment.